Leukocyte Function in Chronic Obstructive Pulmonary Disease (COPD)

NCT00147082 | Completed Results

• 1 other identifier: 01-024
• Study Type: observational
• Target: 100
• Locations: 1 country
• Sites: 1

Brief Summary

The aim of this study is to investigate the mechanisms whereby leukocytes are recruited to the lung in chronic obstructive pulmonary disease (COPD) and cause tissue destruction. The hypothesis is that in COPD more leukocytes enter the lung and it is these cells that are responsible for the degradation of lung tissue. We, the researchers at Imperial College London, will isolate leukocytes from the blood of patients with COPD, healthy smokers and normal subjects and measure the movement of the leukocytes to chemoattractants. We will examine further, which cell surface receptors are responsible for this trafficking of cells. Furthermore, the differentiation of these cells in vitro will be compared with cells from healthy smokers and normal subjects. Specifically, the expression of enzymes that are responsible for tissue destruction and the cell surface receptors on these cells will be investigated. The objective is to identify the mechanisms whereby leukocytes from COPD patients behave differently to cells from healthy smokers and normal subjects with a view to identify novel targets for drug therapy.

Conditions

COPD; Emphysema; Chronic Bronchitis

Keywords

chemokine; chemokine receptor; neutrophil; lymphocyte; monocyte

Outcome Measures

Primary Outcomes (3)

• Effective Concentration (EC 50) of GRO Alpha

  Migration response of PBMC to Chemokine EC 50 represents the concentration of a drug that is required for 50% inhibition in vitro

  2 hours

• Effective Concentration of IL-8

  Migration response of PBMC to Chemokine EC 50 represents the concentration of a drug that is required for 50% inhibition in vitro

  2 hours

• Effective Concentration of MCP-1

  Migration response of PBMC to Chemokine

  2 hours

Study Arms (3)

COPD

Patients with COPD - no intervention

Smokers without COPD

Smokers without COPD - no intervention

Non-smokers

Non-smokers with no history of respiratory disease - no intervention

Eligibility Criteria

• Age: 21 Years - 70 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients who had taken inhaled or oral steroids or who had suffered an exacerbation of their airway disease in the previous 6 weeks were excluded.

You may qualify if:

• Healthy Non-Smoking Subjects. All normal volunteers will meet the following criteria:
• Age 21-70 years.
• No history of respiratory or allergic disease.
• Normal baseline spirometry as predicted for age, sex and height.
• Non-smokers.
• No history of upper respiratory tract infection in the preceding six weeks.
• Not taking regular medication
• COPD Subjects. COPD is diagnosed according to American Thoracic Society, European Respiratory Society and British Thoracic Society guidelines. All COPD volunteers will meet the following criteria:
• Age between 40-75 years.
• A smoking history of at least 20 pack years. (1 pack year = 20 packs of cigarettes per day for 1 year)
• Forced expiratory volume at 1 second : Forced vital capacity (FEV1:FVC) ratio of \<0.7, post-bronchodilator FEV1 of \<85% predicted, reversibility with inhaled beta2-agonist of \<15% of predicted FEV1: all three criteria are required.
• Current smokers or smokers who had ceased smoking for at least 6 months.
• No history of exacerbation, oral steroid or antibiotic use within the preceding 6 weeks.
• Normal serum alpha-1 antitrypsin level.
• No history of other respiratory or allergic disease.

You may not qualify if:

• Clinically significant findings in the medical history or on physical examination other than those of COPD in the COPD group.
• Pregnant women or mothers who are breastfeeding.
• Subjects who are unable to give informed consent.

Sponsors & Collaborators

• Imperial College London: lead

Study Sites (1)

Royal Brompton Hospital/NHLI Imperial College London

London, SW3 6LY, United Kingdom

Location

Related Publications (1)

• Traves SL, Smith SJ, Barnes PJ, Donnelly LE. Specific CXC but not CC chemokines cause elevated monocyte migration in COPD: a role for CXCR2. J Leukoc Biol. 2004 Aug;76(2):441-50. doi: 10.1189/jlb.1003495. Epub 2004 May 20.

  PMID: 15155777 RESULT

Biospecimen

Retention: SAMPLES WITH DNA

Blood

MeSH Terms

Conditions

Pulmonary Disease, Chronic Obstructive; Emphysema; Bronchitis, Chronic

Condition Hierarchy (Ancestors)

Lung Diseases, Obstructive; Lung Diseases; Respiratory Tract Diseases; Chronic Disease; Disease Attributes; Pathologic Processes; Pathological Conditions, Signs and Symptoms; Bronchitis; Respiratory Tract Infections; Infections; Bronchial Diseases

Results Point of Contact

• Title: Professor Louise Donnelly
• Organization: Imperial College London

l.donnelly@imperial.ac.uk

+442075947895

Study Officials

• Louise E Donnelly, PhD

  Imperial College London

  PRINCIPAL INVESTIGATOR

Publication Agreements

• PI is Sponsor Employee: Yes

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 6, 2005
• First Posted: September 7, 2005
• Study Start: February 1, 2001
• Primary Completion: December 1, 2004
• Study Completion: April 1, 2007
• Last Updated: December 5, 2019
• Results First Posted: December 5, 2019

Record last verified: 2019-12

Data Sharing

• IPD Sharing: Will not share

Locations

GB (1)